Today: 30 June 2026
Browse Category

NYSE:GPK 9 December 2025 - 8 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics, SLM Corp, Kontoor Brands and Waystar Holding. Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move are: StockScan
10 December 2025
···········
Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging Holding Company — a major player in sustainable consumer packaging — is having a rough day on Wall Street. As of December 9, 2025, the stock has slid to a new 52-week low after the company cut its full-year earnings outlook, announced cost and production optimization measures, and confirmed a CEO transition set for early 2026. Investing.com India+1 Below is a detailed look at what’s happening with GPK stock today, the latest company news, analyst forecasts, and what the current market narrative looks like.
9 December 2025
··

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop